BridgeMD
Deferoxamine in Aneurysmal Subarachnoid Hemorrhage trial
EU CTIS ID: 2024-514615-10-01
What this study is testing
This study investigates the effects of deferoxamine use in patients with aneurysmal subarachnoid hemorrhage. The primary outcome measure is the presence of new ischemia at control imaging (2 weeks and 6 months). Secondary outcome measures are serum ferritine and various neurological and functional outcomes scales (mRS, GOS-E, EQ-5D) at 6 months.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 18-85 years old inclusive
- Subarachnoid hemorrhage diagnosed by CT on admission
- No history of possible traumatic origin of subarachnoid hemorrhage,
- Eligible for inclusion within 72 hours of subarachnoid hemorrhage
- Saccular intracranial aneurysm proven by cerebral angiography or CTA
- Surgical or endovascular obliteration is successfully performed
You likely can't join if
- Patients not able to give informed consent
- The presence of 4 or more of the following risk modifiers for ARDS prior to enrollment: Tachypnea (respiratory rate >30), SpO2 <95%, Obesity (BMI >30), Acidosis (pH <7.35), Hypoalbuminemia (albumin <3.5 g/dL), Concurrent use of chemotherapy
- Pregnancy, as confirmed by routine urine test on admission
- Abnormal renal function at time of inclusion (eGFR <60 mL/min/1.73m2)
- Elevated liver function test at time of inclusion (AST > 35 U/L and ALT > 45 U/L.)
- History of liver disease or active liver or renal disease
See the full eligibility criteria
- 18-85 years old inclusive
- Subarachnoid hemorrhage diagnosed by CT on admission
- No history of possible traumatic origin of subarachnoid hemorrhage,
- Eligible for inclusion within 72 hours of subarachnoid hemorrhage
- Saccular intracranial aneurysm proven by cerebral angiography or CTA
- Surgical or endovascular obliteration is successfully performed
- Able to obtain written informed consent from patient
- Patients in good clinical grade (WFNS 1-3) (GCS 13-15) at time of randomization
- Patients not able to give informed consent
- The presence of 4 or more of the following risk modifiers for ARDS prior to enrollment: Tachypnea (respiratory rate >30), SpO2 <95%, Obesity (BMI >30), Acidosis (pH <7.35), Hypoalbuminemia (albumin <3.5 g/dL), Concurrent use of chemotherapy
- Pregnancy, as confirmed by routine urine test on admission
- Abnormal renal function at time of inclusion (eGFR <60 mL/min/1.73m2)
- Elevated liver function test at time of inclusion (AST > 35 U/L and ALT > 45 U/L.)
- History of liver disease or active liver or renal disease
- Patients with low ferritine (< 20 µg/L)
- Hypersensitivity to deferoxamine
- Patient taking medication not recommended for concomitant use with deferoxamine as per the product label (e.g. high dose vit. C medication)
- Patients not able to undergo MRI (due to contraindications such as having ferromagnetic or electrical metal implants or not being able to lie still for the duration of the scan)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.